![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/shareholding/consultant-group-hustle-0uykwxuzpbn517dp.jpg)
Share the post "GENOMIC VALLEY BIOTECH Reports Q2: Revenue Up by 201.47% Year-on-Year"
Highlights
- The presented financial data is Standalone to provide a comprehensive overview of the company performance.
- Sales over the Year and quarter: The company experienced a substantial growth of 201.47 % in the past year, substantial increase in net sales/revenue by 32.26 %.
- Profit over the Year and quarter: Significant improvement in profitability for GENOMIC VALLEY BIOTECH LIMITED. Notable increase of 543.48 % in net profit Year to Year, GENOMIC VALLEY BIOTECH LIMITED’s profitability increased by 15.63 % in this quarter.
- EPS over the Year and quarter: EPS increased by 500.00 % Year to Year. EPS increased by 14.29 % in previous quarter. Positive impact on shareholders.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 0.068 Cr | Rs. 0.155 Cr | Rs. 0.205 Cr | + 32.26 % | + 201.47 % |
| Expenses | Rs. 0.04 Cr | Rs. 0.03 Cr | Rs. 0.06 Cr | + 100 % | + 50 % |
| Operating Profit | Rs. 0.03 Cr | Rs. 0.13 Cr | Rs. 0.15 Cr | + 15.38 % | + 400 % |
| OPM % | 44.12 % | 83.87 % | 73.17 % | -10.7 % | + 29.05 % |
| Other Income | Rs. 0 Cr | Rs. 0 Cr | Rs. 0.007 Cr | 0 % | 0 % |
| Interest | Rs. 0 Cr | Rs. 0 Cr | Rs. 0 Cr | 0 % | 0 % |
| Depreciation | Rs. 0 Cr | Rs. 0 Cr | Rs. 0 Cr | 0 % | 0 % |
| Profit before tax | Rs. 0.03 Cr | Rs. 0.13 Cr | Rs. 0.16 Cr | + 23.08 % | + 433.33 % |
| Tax % | 0 % | 0 % | 0 % | 0 % | 0 % |
| Net Profit | Rs. 0.02 Cr | Rs. 0.13 Cr | Rs. 0.15 Cr | + 15.38 % | + 650 % |
| EPS in Rs | Rs. 0.08 | Rs. 0.42 | Rs. 0.48 | + 14.29 % | + 500 % |
Today, we’re looking at GENOMIC VALLEY BIOTECH LIMITED’s financial performance for the Q2(Sep 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 201.47 %. However, it did see a marginal increase of 32.26 % from the previous quarter. Expenses ticked up slightly by 100 % quarter-on-quarter, aligning with the annual rise of 50 %. Operating profit, while up 400 % compared to last year, faced a quarter-on-quarter increase of 15.38 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 29.05 %, but a shrinkage of -10.7 % sequentially. Profit before tax grew annually by 433.33 % but saw an increase from the preceding quarter by 23.08 %.
Net profit rose by 650 % year-on-year but experienced a 15.38 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 500 % but a quarterly rise of 14.29 %. In summary, GENOMIC VALLEY BIOTECH LIMITED’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 0.068 Cr | Rs. 0.155 Cr | Rs. 0.205 Cr | + 32.26 % | + 201.47 % |
| Expenses | Rs. 0.04 Cr | Rs. 0.03 Cr | Rs. 0.06 Cr | + 100 % | + 50 % |
| Operating Profit | Rs. 0.03 Cr | Rs. 0.13 Cr | Rs. 0.15 Cr | + 15.38 % | + 400 % |
| Net Profit | Rs. 0.02 Cr | Rs. 0.13 Cr | Rs. 0.15 Cr | + 15.38 % | + 650 % |
| EPS in Rs | Rs. 0.08 | Rs. 0.42 | Rs. 0.48 | + 14.29 % | + 500 % |
In reviewing GENOMIC VALLEY BIOTECH LIMITED’s 2024(Q2) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 201.47 % year-on-year growth, however, there was a minor increase of 32.26 % from the previous quarter. Expenses rose by 50 % compared to the previous year, with a 100 % increase quarter-on-quarter. Operating Profit surged by 400 % annually, and saw a 15.38 % increase from the last quarter.
Net Profit showed yearly increase of 650 %, and experienced a 15.38 % increase from the previous quarter. Earnings Per Share (EPS) rose by 500 % annually, however rose by 14.29 % compared to the last quarter. In essence, while GENOMIC VALLEY BIOTECH LIMITED exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
27
3-Year Profit
-39
5-Year Profit
0
10-Year Profit
52.2
Current Price
16.0
Market Cap
Upon examining the financial data for BSE code 539206, it becomes clear that the company achieved a notable five-year profit of -39 percents, which impressively increased to 27 percents in the three-year window. This upward trajectory, however, has been overshadowed by the latest trailing twelve-month (TTM) figures, which indicate a concerning loss of -75 percents. This financial loss is further compounded by the fact that the company has not recorded any sales across any of the timeframes under consideration. Such an unusual situation might suggest that the company operates under an unconventional business model, which could potentially carry higher risks. In terms of stock performance, the company’s stock price has seen a decline, falling from 0 percents over the five-year period to just 359 percents in the last year. The ten-year average stock price, which sits at 0 percents, highlights long-term volatility, casting doubt on the company's ability to sustain its market position over time. This warrants further investigation into the factors driving these fluctuations.
The company has a market capitalization of ₹16.0 crore and is currently trading at a stock price of ₹52.2. Over time, the stock has fluctuated between the historical highs and lows of ₹64.2 / 20.6, reflecting the market's volatility. With a Price-to-Earnings (P/E) ratio of 798, the stock appears highly valued, indicating that investors are willing to pay a premium for its earnings potential. The company's book value per share stands at ₹11.6, showcasing the underlying asset value. Additionally, the dividend yield is 0.00%, suggesting that the company offers shareholders a moderate return on their investment in the form of dividends. The Return on Capital Employed (ROCE) is 0.57%, indicating the efficiency with which the company generates profit from its capital. Meanwhile, the Return on Equity (ROE) is 0.57%, highlighting the profitability relative to shareholder equity. Despite these figures, the company maintains a very low debt-to-equity ratio of 0.00, signaling minimal leverage. It also reports a net cash flow of ₹-0.04 crore, reflecting the company's ability to generate cash. The Piotroski score is 4.00, a measure of the company's financial strength, while the Graham Number estimates the intrinsic value of the stock at ₹4.13. The Price-to-Book (P/B) ratio of 4.51 further suggests that the stock is trading at a premium relative to its book value, potentially reflecting positive market sentiment or expectations of future growth.
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/CHEMCON.png)
